Recent advances on diagnosis and therapy of lymphoproliferative disorders after allo-HSCT.
10.7534/j.issn.1009-2137.2014.02.051
- Author:
Bin GU
1
;
Guang-Hua CHEN
1
;
De-Pei WU
2
Author Information
1. Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.
2. Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China. E-mail: wudepei@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Epstein-Barr Virus Infections;
diagnosis;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Herpesvirus 4, Human;
Humans;
Lymphoproliferative Disorders;
diagnosis;
etiology;
therapy;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2014;22(2):538-542
- CountryChina
- Language:Chinese
-
Abstract:
Post-transplant lymphoproliferative disorders(PTLD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are a group of rare, but are grievous complications. The occurrence of these diseases are most associated with EBV infection. The clinical manifestations usually include recurrent fever, lymph node enlargement, progressive decline of three lineage cells of hemogram, EB viremia and response failure to formal broad-spectrum antibiotics therapy, then the disease rapidly deteriorated in the short term, which result in high mortality. Therefore, early diagnosis and timely effective treatment such as rituximab, donor lymphocyte infusion and/or EB virus-specific cytotoxic T lymphocytes are needed to improve the prognosis. This review briefly summarized the diagnosis and therapy advance on the lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
